Ophthalmologists evaluating new NAION cases should inquire about semaglutide exposure, and patients diagnosed while on therapy should inform their prescribing clinicians. Consideration of baseline ocular risk factors, including prior NAION or existing optic nerve disease, may also inform treatment discussions. READ MORE: Regaining Vision with Optic Nerve Cell Regeneration Understanding the mechanism The biologic mechanism underlying the association remains uncertain
An ideal 3-month InBody result on semaglutide with appropriate support shows: body fat mass reduced by 24 kg, skeletal muscle mass stable or minimally changed (within 0.3 kg of baseline), visceral fat level reduced by at least 1 level, BMR within 75100 kcal of baseline, and phase angle stable or improved
This is totally normal and usually settles down within a week or two as your skin adjusts
Increased urination, sometimes seen with GLP-1 receptor agonists like semaglutide, can lead to dehydration if fluid intake isnt carefully managed
Pemvidutide's Double Threat Altimmune's lead candidate, Pemvidutide, addresses both obesity and liver disease as they two can be linked